These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 25171298)
1. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. Gurka MK; Kim C; He AR; Charabaty A; Haddad N; Turocy J; Johnson L; Jackson P; Weiner LM; Marshall JL; Collins SP; Pishvaian MJ; Unger K Am J Clin Oncol; 2017 Apr; 40(2):152-157. PubMed ID: 25171298 [TBL] [Abstract][Full Text] [Related]
2. Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer. Lischalk JW; Burke A; Chew J; Elledge C; Gurka M; Marshall J; Pishvaian M; Collins S; Unger K J Gastrointest Cancer; 2018 Jun; 49(2):116-123. PubMed ID: 28044263 [TBL] [Abstract][Full Text] [Related]
3. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019 [TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581 [TBL] [Abstract][Full Text] [Related]
5. Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer. Libbey N; Gallagher L; Cantalino J; Weinberg BA; Noel MS; He AR; Radkani P; Marshall JL; Weiner LM; Jackson PG; Fishbein TM; Winslow ER; Haddad N; Rashid A; Unger KR J Gastrointest Cancer; 2024 Jun; 55(2):852-861. PubMed ID: 38347342 [TBL] [Abstract][Full Text] [Related]
6. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. Simoni N; Micera R; Paiella S; Guariglia S; Zivelonghi E; Malleo G; Rossi G; Addari L; Giuliani T; Pollini T; Cavedon C; Salvia R; Milella M; Bassi C; Mazzarotto R Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e31-e38. PubMed ID: 32682686 [TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Park JJ; Hajj C; Reyngold M; Shi W; Zhang Z; Cuaron JJ; Crane CH; O'Reilly EM; Lowery MA; Yu KH; Goodman KA; Wu AJ Acta Oncol; 2017 Dec; 56(12):1746-1753. PubMed ID: 28661823 [TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. de Geus SWL; Eskander MF; Kasumova GG; Ng SC; Kent TS; Mancias JD; Callery MP; Mahadevan A; Tseng JF Cancer; 2017 Nov; 123(21):4158-4167. PubMed ID: 28708929 [TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768 [TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Gurka MK; Collins SP; Slack R; Tse G; Charabaty A; Ley L; Berzcel L; Lei S; Suy S; Haddad N; Jha R; Johnson CD; Jackson P; Marshall JL; Pishvaian MJ Radiat Oncol; 2013 Mar; 8():44. PubMed ID: 23452509 [TBL] [Abstract][Full Text] [Related]
11. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancerĀ (CRiSP): An international systematic review and meta-analysis. Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712 [TBL] [Abstract][Full Text] [Related]
12. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma. Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311 [TBL] [Abstract][Full Text] [Related]
13. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605 [TBL] [Abstract][Full Text] [Related]
14. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer. Wu G; Baine MJ; Zhao N; Li S; Li X; Lin C BMC Cancer; 2019 Oct; 19(1):977. PubMed ID: 31640607 [TBL] [Abstract][Full Text] [Related]